Biocon's drug receives approval for use on coronavirus patients

Biocon's drug Itolizumab has received regulatory approval from the Drug Controller General of India to be used on coronavirus patients suffering from moderate to severe respiratory distress. It's the first novel biological therapy to be approved by the DCGI.

Biocon's chaiperson, Kiran Mazumdar Shaw said that in a randomised control trial, all patients administered with this drug responded positively and recovered, while those who did not unfortunately suffered casualties.